Exelixis | EXEL - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bayer EUR 3.7B 356M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
Eisai JPY 119.54B 7.82B 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Genmab DKK 208M 60M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.67B 180M 2026-03
Moderna USD 173M 135M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sanofi EUR 2.75B 455M 2025-12
Takeda JPY 292B 9.21B 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Xencor USD 82.12M 65.08M 2026-03